Prevalence and progression of mitochondrial diseases: A study of 50 patients
ABSTRACT We report 50 patients with various clinical phenotypes of mitochondrial disease studied over the past 10 years in a large urban area (Madrid Health Area 5). The clinical phenotypes showed a large variety of abnormalities in molecular biology and biochemistry. The prevalence of mitochondrial diseases was found to be 5.7 per 100,000 in the population over 14 years of age. Clinical and electrophysiological assessment reveal signs of neuropathy in 10 patients. Electromyographic findings consistent with myopathy were obtained in 37 cases. Six patients died of medical complications. Disease phenotype influenced survival to some degree (P < 0.01). Age of onset and gender were not associated with differences in survival. Mitochondrial disease is thus far more common than expected and a common cause of chronic morbidity.
- SourceAvailable from: Mirna Duarte Barros[Show abstract] [Hide abstract]
ABSTRACT: Mitochondria are organelles responsible for production of most energy through oxidative phosphorylation process (OXPHOS). It contains a double strand DNA (mitDNA) of about 16,500 bp encoding two ribosomal RNAs and 37 mitochondrial proteins. Mutation in mitDNA may result in multisystem syndromes known as mitochondrial diseases, affecting predominantly tissues that require high levels of ATP such as skeletal muscle (mitochondrial myopathies), brain (e.g. MELAS, MERRF, LHON e NARP), liver, kidney (Fanconi syndrome), heart and endocrine glands (Pearson syndrome). A case of mitochondrial disease was first reported in 1962 and correlation of such disease with mutations in mitDNA gained scientific importance in late 1980's. There are 150 alterations reported in mitDNA capable of producing metabolic dysfunctions of clinical relevance. To date, no standard protocol for diagnosis of mitochondrial diseases has been established, partially due to the wide amplitude of clinical manifestation generally observed. A combined analysis of clinical data, biochemical, morphological and laboratory tests must be performed to evaluate mitochondrial respiratory chain activity and integrity of nuclear and mitochondrial genomes. Currently, there are no effective treatments available for mitochondrial diseases, but only palliative therapeutics using conventional strategies to relieve symptoms. Thus, gene therapy emerges as potential therapeutic strategy for more efficient treatment of mitochondrial diseases.
Conference Paper: Monolithic gallium arsenide receiver for NMR microscopy[Show abstract] [Hide abstract]
ABSTRACT: The goal of this research is to improve the performance of NMR microscopy systems by fabricating the RF detection microcoil and preamplifier on a single monolithic GaAs substrate. The planar microcoil consists of 4-7 turns of gold conductor. A simple impedance matching network links the microcoil to a single stage, common source configuration, GaAs MESFET preamplifierEngineering in Medicine and Biology Society, 1994. Engineering Advances: New Opportunities for Biomedical Engineers. Proceedings of the 16th Annual International Conference of the IEEE; 02/1994
- [Show abstract] [Hide abstract]
ABSTRACT: Mitochondrial disease is frequently a multisystem disorder which often involves the central nervous system. Imaging finding although diverse are characterized by focal lesions with T2 hyperintensity, which may be most evident on FLAIR imaging and often progress to atrophy. Deep brain structures including brainstem and basal ganglia structures are particularly vulnerable though white matter and cortex may also be involved. In this paper we describe in detail the imaging features of the spectrum of mitochondrial diseases and suggest a scoring technique for recording severity and extent of brain involvement. Although there is overlap between the imaging features of disease phenotypes, magnetic resonance imaging may be useful in supporting the clinical diagnosis. There is little correlation between molecular defect and imaging findings with some noticeable exceptions such as the MELAS syndrome.Mitochondrion 10/2004; 4(5-6):471-90. DOI:10.1016/j.mito.2004.07.008 · 3.52 Impact Factor